Jonathan Zalevsky Sells 5,681 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock

Nektar Therapeutics (NASDAQ:NKTR) insider Jonathan Zalevsky sold 5,681 shares of Nektar Therapeutics stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $70.00, for a total transaction of $397,670.00. Following the completion of the transaction, the insider owned 9,756 shares of the company’s stock, valued at $682,920. The trade was a 36.80% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Jonathan Zalevsky also recently made the following trade(s):

• On Monday, June 15th, Jonathan Zalevsky sold 5,538 shares of Nektar Therapeutics stock. The shares were sold at an average price of $60.71, for a total transaction of $336,211.98.
• On Tuesday, May 19th, Jonathan Zalevsky sold 199 shares of Nektar Therapeutics stock. The stock was sold at an average price of $65.51, for a total value of $13,036.49.

Nektar Therapeutics Price Performance

Shares of Nektar Therapeutics stock traded up $6.65 during trading hours on Thursday, reaching $71.04. The company had a trading volume of 1,119,058 shares, compared to its average volume of 1,228,223. The firm has a market cap of $2.40 billion, a PE ratio of -8.44 and a beta of 1.13. Nektar Therapeutics has a one year low of $21.02 and a one year high of $109.00. The business has a fifty day simple moving average of $69.60 and a 200 day simple moving average of $62.77.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.58) by ($0.24). Nektar Therapeutics had a negative return on equity of 85.40% and a negative net margin of 284.18%.The company had revenue of $10.86 million for the quarter, compared to analysts’ expectations of $10.69 million. On average, research analysts forecast that Nektar Therapeutics will post -9.45 EPS for the current year.

Hedge Funds Weigh In On Nektar Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in NKTR. BNP Paribas Financial Markets grew its position in Nektar Therapeutics by 93.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 210 shares during the last quarter. KBC Group NV bought a new stake in Nektar Therapeutics in the first quarter valued at $52,000. State of Wyoming purchased a new position in Nektar Therapeutics during the 1st quarter valued at $67,000. Quarry LP purchased a new stake in shares of Nektar Therapeutics in the 4th quarter worth about $85,000. Finally, Flagship Harbor Advisors LLC purchased a new position in shares of Nektar Therapeutics during the fourth quarter valued at about $92,000. Institutional investors own 75.88% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on NKTR shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nektar Therapeutics in a report on Tuesday, June 2nd. Wall Street Zen upgraded Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, May 17th. BTIG Research lifted their price objective on Nektar Therapeutics from $151.00 to $178.00 and gave the company a “buy” rating in a research note on Monday, April 20th. Jefferies Financial Group restated a “buy” rating on shares of Nektar Therapeutics in a research note on Wednesday, April 22nd. Finally, Citigroup boosted their price objective on Nektar Therapeutics from $123.00 to $151.00 and gave the stock a “buy” rating in a report on Tuesday, April 21st. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $149.62.

Nektar Therapeutics Company Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.